1. Scrip
  2. >>Business
  3. >>Financing

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

First Financing Since $20m Seed Round In 2021

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

HAYA is searching the dark genome for long non-coding RNA targets (Shutterstock)

HAYA Therapeutics formed around co-founder and CEO Samir Ounzain’s discovery of a long non-coding RNA (lncRNA) known as Wisper, associated with fibrosis in the heart, and developed a platform to search the dark genome for lncRNAs that could be targeted to treat the root cause of common and chronic diseases. Four years after raising its seed round and seven months after entering into a collaboration with Eli Lilly, the company closed a $65m series A round.

Key Takeaways
  • HAYA raised $65m in series A venture capital to take its lead asset, HTX-001 for nHCM, into the clinic. The start-up advanced its lncRNA-targeting platform...

Lausanne, Switzerland-based HAYA, which keeps a US base in San Diego, announced the new funding on 8 May – its first major financing since its CHF18m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.